資源描述:
《尤瑞克林治療輕-中度急性腦梗死的臨床療效觀察》由會員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、尤瑞克林治療輕中度急性腦梗死的臨床療效觀察 [摘要]目的:探討尤瑞克林對輕、中度急性腦梗死的臨床效用。方法:將40例輕、中度急性腦梗死的患者隨機(jī)分為治療組和對照組。治療組20例采用尤瑞克林治療。對照組20例采用丹參治療。對治療前、后進(jìn)行臨床神經(jīng)功能缺損程度的評定和療效評分。測定治療前、后平均血流速度(V)、平均血流量(Q)和外周血管阻力(R),全血黏度、血小板聚集率、紅細(xì)胞壓積。結(jié)果:治療組有效率明顯高于對照組(P<0.05)。治療組用藥后2周與用藥前比較,治療組與對照組治療后比較:平均血流速度(V)和平均血流量(Q)均明顯增加(P<0.05),外周血管阻力(R)均明顯降低(P<0
2、.05);用藥后2周,治療組和對照組全血高切、低切黏度和血小板聚集率、紅細(xì)胞壓積均無顯著性差異(P>0.05)。結(jié)論:尤瑞克林治療輕、中度急性腦梗死安全有效?! 關(guān)鍵詞]輕、中度急性腦梗死;尤瑞克林;臨床療效 ClinicalcurativeeffectobservationonHumanUrinaryKallidinogenaseintreatmentoflightly,themoderateacutecerebralinfarction LIUYuting,CHENXiaofei (DepartmentofNeurology,ShanxiCardiovascularHo
3、spital,Taiyuan030024,China) [Abstact]Objective:ToobserveclinicalcurativeeffectofHumanUrinaryKallidinogenasetreatslightly,themoderateacutecerebralinfarction.Methods:40exampleslight,themoderateacutecerebralinfarctionpatiententgroupandthecontrolgroup,randomly.Thetreatmentgroup(n=20)anUrinaryKallid
4、inogenase,thecontrolgroup(n=20)iltiorrhiza.Beforeandaftertreatment,evaluatedtheclinicalnervefunctiondamagedegreetheionandcurativeeffectgrading.Determinateaveragebloodstreamspeed(V),theaveragebloodstreammeasures(Q)andcircumferencebloodvesselresistance(R),theulationrate,theredbloodcellpressesthepr
5、oductbeforeandafterthetreatment.Results:Treatmentgroupeffectivenessedicationparededication:thetreatmentgroupapplieddrugslater2edicationentgroupandthecontrolgroupspeed(V)andtheaveragebloodstreammeasure(Q)increasedobviously(P<0.05),circumferencebloodvesselresistance(R)reducedobviously(P<0.05);thet
6、reatmentgroupandthecontrolgroupapplieddrugslater2ulationrate,theredbloodcellpressureaccumulatesarkablechanges(P>0.05),non-statisticsdifference.Conclusion:HumanUrinaryKallidinogenasetreatslightly,themoderateacutecerebralinfarctionissafeandeffective. [Keyoderateacutecerebralinfarction;HumanUrinar
7、yKallidinogenase;Clinicalcurativeeffect 腦梗死是危害人類健康的最嚴(yán)重的疾病之一,它的發(fā)病率、致死率、致殘率均很高[1]。溶栓治療雖然有效,但有嚴(yán)格的時(shí)間窗及適應(yīng)證,因此應(yīng)用范圍有限。尤瑞克林(人尿激肽原酶,HumanUrinaryKallidinogenase),商品名:凱力康,為廣東天普生化醫(yī)藥有限公司生產(chǎn)的國家一類新藥,天普公司擁有該項(xiàng)目的自主知識產(chǎn)權(quán)(專利號:021167834)。尤瑞克林是從